US 2002/0054852 A1Published application

System and method for the local delivery of drugs

OwnerFolkert Jan ten Cateinventor

Life of this patent

Estimating the term…

Loading patent…

Abstract

A method of treating a specific site in a mammal with a drug comprises (a) providing a carrier material which reflects or absorbs or emits electromagnetic or mechanical vibrations enabling the monitoring of the carrier material, (b) providing a drug associated with the carrier material, (c) providing a targeting agent associated with the carrier material, the targeting agent being capable of binding to the specific site in the mammal, (d) delivering the carrier material and the drug to the specific site in the mammal, and (e) monitoring the mammal to detect arrival of the carrier material at the specific site. A local and site-specific drug delivery system for delivering a drug to a specific site within an individual comprises a carrier material which reflects or absorbs or emits electromagnetic or mechanical vibrations enabling the monitoring of the carrier material, a drug associated with the carrier material, and a targeting agent associated with the carrier material that delivers the carrier material and the drug to a specific site within the individual, the targeting agent being capable of binding to the specific site within the individual.

Claims33

Dependent claims

A method of treating a specific site in a mammal with a drug, said method comprising:

(a) providing a carrier material which reflects or absorbs or emits electromagnetic or mechanical vibrations enabling the monitoring of said carrier material;
(b) providing a drug associated with said carrier material, said drug being selected from the group consisting of acebutolol, acetylsalicylic acid, adenosine, ATP, alfentanil, alprazolam, azlocillin, betamethasone, bleomycin, captopril, carbenicillin, cefamandole, cefazolin, cefonicid, ceforanide, cefotaxime, cefoxitin, clonidine, cloxacillin, cyclophosphamide, cytarabine, dexamethasone, dicloxacillin, diazepam, diazoxide, digitoxin, digoxin, diltiazem, diphenihydramine, disopyramide, doxorubicin, doxycycline, ceftazidime, ceftizoxime, cefuroxime, cephalexin, cephalothin, cephapirin, chloramphenicol, chloroquine, chlorothiazide, chlorpropormide, chlorthalidone, cimetidine, clofibrate, ibuprofen, imipramine, indomethacin, isosorbide dinitrate, ketoprofen, labetalol, lidocaine, lorazepam, lorcainide, meperidine, mercaptopurine, methadone, methicillin, erythromycin, ethambutol, fentanyl, flucytosine, flunitrazepam, fluorouracil, flurazepam, furosemide, gold sodium thiomalate, haloperidol, heparin, hexobarbital, hydrochlorothiazide, nortriptyline, oxacillin, oxazepam, phenobarbital, phenylbutazone, phenytoin, pindolol, prazosin, prednisolone, prednisone, protenecid, procainamide, propranolol, methothexate, methyldopa, methylprednisolone, metoprolol, metronidazole, mexiletine, mezlocillin, minocycline, morphine, moxalactam, nadolol, nafcillin, naproxen, nifedipine, nitrazepam, theopental, ticarcillin, timolol, tocainide, tolbutamide, tolmetin, triamterene, triazolam, trimethoprim, tubocurarine, valproic acid, verapamil, warfarin, protriptyline, pyrimethamine, quinidine, ranitidine, rifampin, salicylic acid, streptomycin, streptokinase, sulfadiazine, sulfamethoxazole, sulfisoxazole, ternazepam, terbutaline, tetracycline, theophylline, and tissue plasminogen activator (tpa);
(c) providing a targeting agent associated with said carrier material, said targeting agent being capable of binding to said specific site in the mammal;
(d) delivering said carrier material and said drug to said specific site in the mammal;
and
(e) monitoring the mammal to detect arrival of said carrier material at said specific site.

3 more elements

A method of treating a specific site in a mammal with a drug, said method comprising:

(a) providing a carrier material which reflects or absorbs or emits electromagnetic or mechanical vibrations enabling the monitoring of said carrier material;
(b) providing a drug associated with said carrier material;
(c) providing a targeting agent associated with said carrier material, said targeting agent being capable of binding to said specific site in the mammal;
(d) delivering said carrier material and said drug to said specific site in the mammal;
and
(e) monitoring the mammal to detect arrival of said carrier material at said specific site.

3 more elements

A method of delivering a drug to a specific target site in an individual, said method comprising:

(a) administering an ultrasonic contrast agent-drug complex to a specific target site in an individual, said complex comprising an ultrasonic contrast agent, a drug, and a targeting agent capable of binding said ultrasonic contrast agent to said specific target site in the individual;
(b) monitoring the individual using ultrasound to determine arrival of said complex at said specific target site in the individual;
and
(c) releasing said drug at said specific target site by applying sufficient energy to rupture said complex at said specific target site.

1 more element

A local and site-specific drug delivery system for delivering a drug to a specific site within an individual, said drug delivery system comprising:

a carrier material which reflects or absorbs or emits electromagnetic or mechanical vibrations enabling the monitoring of said carrier material;
a drug associated with said carrier material;
and
a targeting agent associated with said carrier material that delivers said carrier material and said drug to a specific site within the individual, said targeting agent being capable of binding to said specific site within the individual.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 10/022,021Filed 13 Dec 2001
Priority: 19 Jan 1995
Published: 9 May 2002
Term ends: Not estimatedThe source records don’t support an estimate.

Classification4 codes

A61K 41/00
Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/6921
The conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit: the form being a…
A61K 49/223
Characterised by a special physical form, e.g. emulsions, liposomes: microbubbles, hollow microspheres, free gas bubbles, gas microspheres
A61K
Medicines and medical preparations

Family

Application08/893,206Division · filed 15 Jul 1997
Application08/893,206Continuation in part · filed 15 Jul 1997
Application10/022,021Division · filed 13 Dec 2001
US 6,352,683 B1Related patent
US 2002/0054852 A1This patent

From the US filing history. Foreign family members aren’t listed.